Summary of Key Information:
Reporting Period (Quarter/Year): Quarter ended June 30, 2026 (Q1 FY27)
Nature of Filing / Announcement: Outcome of Board Meeting - Unaudited Financial Results
Audit Opinion:
Unmodified opinion (clean) for both standalone and consolidated financial results
Key Financial Highlights [Rs in Mn]:
Standalone Results:
Revenue from Operations: ₹3,838.42 (QoQ: -34.1% from ₹5,825.01; YoY: -28.7% from ₹5,380.11)
Total Income: ₹4,124.42 (QoQ: -35.9% from ₹6,431.26; YoY: -27.1% from ₹5,657.39)
Net Profit: ₹1,020.09 (QoQ: -51.8% from ₹2,116.65; YoY: -31.2% from ₹1,483.40)
EPS: Basic ₹1.81, Diluted ₹1.80 (not annualized)
Other Equity: Not specified for current quarter
Cash and Cash Equivalents: Not disclosed
Debt: Not disclosed
Consolidated Results:
Revenue from Operations: ₹4,431.06
Total Income: Not separately stated
Net Profit: ₹1,199.41
EPS: Not disclosed
Other Equity: Not disclosed
Cash and Cash Equivalents: Not disclosed
Debt: Not disclosed
Segment-wise Performance [Rs in Mn]:
Segment Revenue:
- CRDMO: ₹3,408.02 (QoQ: -33.5% from ₹5,128.36; YoY: -24.7% from ₹4,527.11)
- Speciality Ingredients: ₹774.16 (QoQ: -21.1% from ₹981.07; YoY: -11.5% from ₹874.98)
- Total Segment Revenue: ₹4,182.18
Segmental Results:
Gross Profits:
- CRDMO: ₹2,322.57 (QoQ: -32.5% from ₹3,438.30; YoY: -12.3% from ₹2,648.72)
- Speciality Ingredients: ₹397.62 (QoQ: -23.0% from ₹516.58; YoY: -10.6% from ₹444.60)
- Total Gross Profit: ₹2,720.20
Corporate Actions:
The company allotted 1,670,909 fully paid-up equity shares of ₹2 each under "ESOP Scheme 2024" following board approvals on May 19, 2026 and June 16, 2026.
Other Significant Information:
The consolidated financial statements include Anthem Biosciences Limited (Parent Company) and Neoanthem Lifesciences Private Limited (wholly owned subsidiary). The subsidiary contributed revenue of ₹358.05 million and net profit of ₹82.22 million for the quarter.